Slide 1: Interim Results for 6 months ended 31 Dec 2020
Interim Results for 6 months ended 31 Dec 2020 Investor Presentation 11 March 2021 Copyright © Physiomics Plc 2021 - www.physiomics.co.uk
Slide 2: Disclaimer
Disclaimer The information contained in this presentation ("Presentation") has been prepared by Physiomics Plc (the "Company"). This Presentation has not been approved by an authorised person in accordance with Section 21 of the Financial Services and Markets Act 2000 (" FSMA"). This Presentation sh
Slide 3: Physiomics is focused on modelling cancer
Physiomics is focused on modelling cancer Knowledge of Modelling of drug cancer levels and effects Ability to access AI/ machine learning and interpret data Slide 3 Copyright © Physiomics Plc 2021 - www.physiomics.co.uk
Slide 4: We work with biotech/ pharma and develop personalised oncology tools
We work with biotech/ pharma and develop personalised oncology tools Supporting oncology R&D Personalised oncology • Analytical and modelling support • Grant funded by Innovate UK & for oncology pre-clinical and NIHR clinical development • Predicts toxicity and response • Full spectrum of modelling
Slide 5: We've completed over 80 commercial and grant funded projects
We’ve completed over 80 commercial and grant funded projects Big pharma Merck, Astellas, MSD, Lilly, Bayer and others Grants NIHR, Innovate UK, EU- >80 Biotech/ Midcap Bicycle Therapeutics, FP6 (TEMPO), Carbon projects CellCentric, Convert completed Trust Pharmaceuticals, and others Academic Medicin
Slide 6: What our clients say about us…
What our clients say about us… Nigel Brooks, Director Translational Science, CellCentric We have worked with Physiomics to help provide answers to some critical early clinical development questions with CCS1477, our novel p300/CBP inhibitor. The analysis performed by Physiomics and the interpretatio
Slide 7: Selected financial highlights: 6 months ended 31 Dec 2020
Selected financial highlights: 6 months ended 31 Dec 2020 • Revenue of £363k (six months ended 31 December 2019: £343k) • Total income of £386k* (six months ended 31 December 2019: £343k*) • 13% ahead of comparable prior period • Operating loss of £132k (six months ended 31 December 2019: £118k) • C
Slide 8: Selected operational highlights: 6 months ended 31 Dec 2020
Selected operational highlights: 6 months ended 31 Dec 2020 • Signing of a further contract with Bicycle Therapeutics; the eighth signed with this high-profile UK biotech company, spanning four different assets within its pipeline • Agreement with Astellas Pharma Inc. to model an undisclosed immune-
Slide 9: Continued revenue growth and good cash management
Continued revenue growth and good cash management Slide 9 Copyright © Physiomics Plc 2021 - www.physiomics.co.uk Source: Physiomics published annual and interim results
Slide 10: Marketing
Marketing • Raise awareness: • Social media (Twitter, LinkedIn) • Website (rebranded/ upgraded Q1 2019) • Identify specific prospects • Database used to identify companies with oncology pipelines • Contact and convert prospects • Telephone marketing via agency • Conferences (e.g. AACR, ASCO, EORTC,
Slide 11: Core consulting business based on modelling & simulation using Virtual Tumour and other tools
Core consulting business based on modelling & simulation using Virtual Tumour™ and other tools • Continuing strong relationships with existing repeat-clients, including CellCentric and Bicycle Therapeutics and Merck KGaA • Eleven follow-on agreements with existing clients in calendar year 2020 and a
Slide 12: Personalised medicine
Personalised medicine • Competed for and won two Innovate UK grants and one NIHR grant over a five-year period, and these funds have and are being used to develop a personalised oncology software tool • The Directors view the agreement with Tabula Rasa Healthcare® relating to the Company’s personali
Slide 13: Investment proposition
Investment proposition • Continued focus and targeted growth in main commercial business of consulting services which relies substantially on our proprietary Virtual Tumour™ technology • Continued investment in marketing & sales • Planned hire of dedicated business development executive • Leveraging
Slide 14: Contacts:
Contacts: • Physiomics plc, info@physiomics.co.uk • Hybridan LLP, Broker, research@hybridan.com Copyright © Physiomics Plc 2021 - www.physiomics.co.uk
Slide 15: Unaudited Income Statement for the 6 months ended 31 Dec 2020
Unaudited Income Statement for the 6 months ended 31 Dec 2020 Source: Physiomics published results Slide 15 Copyright © Physiomics Plc 2021 - www.physiomics.co.uk
Slide 16: Unaudited Statement of Financial Position at 31 Dec 2020
Unaudited Statement of Financial Position at 31 Dec 2020 Source: Physiomics published results Slide 16 Copyright © Physiomics Plc 2021 - www.physiomics.co.uk
Slide 17: Unaudited Cash Flow Statement for the 6 months ended 31 Dec 2020
Unaudited Cash Flow Statement for the 6 months ended 31 Dec 2020 Source: Physiomics published results Slide 17 Copyright © Physiomics Plc 2021 - www.physiomics.co.uk
Slide 18: Board of directors
Board of directors • Dr Paul Harper (Non-Executive Chairman) has over 35 years' experience in the life sciences industry covering both drug development and medical devices. He was a non-executive director of Reneuron Holdings Plc, an AIM quoted company. Paul has served as Chairman of Oval Medical Te